Our Technology in Action
We operate at the interface of translational research and commercialization. At all times, our multidisciplinary team is actively engaged with members of the clinical research community, manufacturers of mass spectrometry technology and clinical laboratories
M-SCOUT integrates a multitude of essential building blocks necessary to successfully identify, quantify and select, combinations of metabolite biomarkers relevant to a certain condition.
PrePsia is a prototype screening test, which identifies in early pregnancy, those women at increased risk of developing preeclampsia later in their pregnancies (Preeclampsia – What is preeclampsia, its causes and symptoms).
Preeclampsia is a disorder specific to pregnancy, which occurs in 5% of 1st time pregnancies. The condition originates in the placenta and manifests as new-onset hypertension and proteinuria after 20 weeks’ gestation.
Metabolomic Diagnostics is your Partner in Translational Research. We are a specialist organisation dedicated to the translation of novel biomarkers for complex diseases into market-ready diagnostic products.
PREeclampsia risk stratification test: development of CALIbration framework for the analysis of a multiplex panel of endogenous Compounds by LC-MS. Metabolomic Diagnostics (METABOL) is an innovative company which is developing tests for preeclampsia in pregnancy.